Govt approves stepping up of Remdesivir Drug production

Manufacturers of Remdesivir have volunteered to reduce the price to less than Rs 3500 by the end of this week to fight against COVID.

| April 15, 2021


#Remdesivir   #CovidVaccine   #Corona   #Coronavaccine   #NationalPharmaceuticalPricingAuthority   #DCGI   #Vaccineexport  
The government has reviewed the issue of availability of Remdesivir Drug and has decided to increase the production and decrease the price of the drug. The government has​ also issued a ban on its export. Remdesivir is the first drug approved by the FDA for treating the SARS-CoV-2 virus. 
 
The review was done by Mansukh Mandaviya, Minister of State, For Ports, Shipping and Waterways (Independent Charge) and Chemicals & Fertilizers, Government of India in meetings with the all-existing manufacturers of the Remdesivir drug and other stakeholders on 12th and 13th April 2021.
 
As an additional measure, Remdesivir, API and formulation were placed under the export ban by DGFT to increase the supply of Remdesivir in the domestic market. On Government intervention, Remdesivir supplies of approximately 4 lakh vials meant for export is being diverted by manufacturers to fulfil the domestic requirement. EOU/SEZ units are also being enabled to supply to the domestic market.
 
Manufacturers of Remdesivir have volunteered to reduce the price to less than Rs 3500 by the end of this week to fight against COVID. Manufactures of Remdesivir have been directed to give priority to fulfil hospital/institutional level supplies. National Pharmaceutical Pricing Authority (NPPA) is continuously monitoring the availability of Remdesivir.
 
Also, DCGI has directed enforcement authorities of states and central government to take immediate action on the incidence of black-marketing, hoarding and overcharging of Remdesivir.
 
The current total installed capacity of the seven manufacturers of Remdesivir is 38.80 lakh vials per month. Fast-track approval has been given for seven additional sites having the production capacity of 10 Lakh vials /month to six manufacturers. Another 30 lakh vials/month production is lined up. This would ramp up the production capacity for manufacturing to around 78 lakh vials/month.
 

Comments

 

Other News

`M`rashtra muni. corpns face major governance, citizen participation gaps`

A statewide consultation organised by Praja Foundation has highlighted major governance, financial, and citizen participation gaps across Maharashtra’s Municipal Corporations, calling for urgent reforms to strengthen urban local bodies in line with the 74th Constitutional Amendment Act. &nb

When children stay healthy, they stay in school

Learning Begins with Wellbeing The future of education is often discussed through the lens of classrooms, technology, and learning outcomes. Yet one of the most critical drivers of a child’s ability to learn remains surprisingly overlooked: their health.  

India lost Rs 52,000 crore to cyber fraud in five years: DoT

India has lost more than Rs 52,000 crore to cyber fraud over the last five years, officials have revealed. Out of approximately 60 lakh cyber fraud complaints received, more  than 3,000 cases have been resolved and six cyber fraud setups have been busted.   On the occ

India must not wait for its own Ella

In many Indian cities, children learn to wear masks before they are old enough to understand why. That reality should alarm us far more than it does.   In 2020, nine-year-old Ella Adoo Kissi Debrah became the first person in the world to have air pollution officially recognized a

An ode to the cradle of humankind

The Alphabets of Africa: Poems By Abhay K. Vintage Classics, 280 pages, ₹499.00   Abhay K

Ahmedabad district railway network to be expanded

The Cabinet Committee on Economic Affairs, chaired by prime minister Narendra Modi, on Wednesday approved the Ahmedabad (Sarkhej) – Dholera Semi High-Speed Double Line project of Ministry of Railways with total cost of Rs. 20,667 crore (approx.). It will be Indian Railways 1st semi high-speed project


Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter